Remedy for psoriasis is collected by a laboratory in the U.S.
This article was translated by an automatic translation system, and was therefore not reviewed by people.
(Source: Folha de S. Paulo, for Julliane Silveira)
The pharmaceutical Genentech announced yesterday that voluntarily withdraw from the market in the U.S. the drug Raptiva (efalizumabe), indicated for severe cases of psoriasis or for patients who do not respond to other treatments. The company says the drug increases risk of the user develop progressive multifocal leukoencephalopathy, a fatal type of infection in the brain.
At the end of 2008, the FDA (U.S. agency that regulates food and drugs) forced the manufacturer to include a warning on the packaging of the drug due to reports of opportunistic infections associated with its use. The EMEA (European Medicines Agency) also issued a warning. Two deaths occurred on the continent resulting from the use of medication.
The Raptiva is marketed in Brazil by the laboratory and Merck Serono has the approval Anvisa (National Health Surveillance Agency), which has not been notified by the company. Merck Serono said that "a month ago, had taken the decision to suspend marketing the drug in all countries which holds the license, including Brazil."
The dermatologist Cid Sabbag, director of the Brazilian Center for Psoriasis, Brazilian physicians received a letter in March in the laboratory with the information that the sale of the product could be reduced and stopped. "The collection will occur in phases, so there is time to make the transition to another medication."
Around 47 thousand people use the medication in the world, says Sabbag-one months of treatment costs $ 5,000. For him, the action is "a bit of exaggeration." "The deaths occur in the elderly, perhaps the immune system is weakened further."
Patients who use drugs should not stop the treatment, at risk of worsening of symptoms of the disease. It is recommended to seek medical attention.
Source: Idec
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Important:
The JurisWay site does not interfere in the work provided by doctrine, why only reflect the opinions, ideas and concepts of their authors.
